Related Experiment Video

Updated: Mar 23, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications

Diana L Hanna1,2, Heinz-Josef Lenz1

  • 1a Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine , University of Southern California , Los Angeles , CA , USA.

Expert Review of Clinical Pharmacology
|April 1, 2016
PubMed

Insights

Metastatic colorectal cancer (mCRC) management advances with new therapies and personalized strategies. This review explores novel treatments, combinations, and pharmacogenomic data for improved patient outcomes.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacogenomics

Background:

  • Colorectal cancer (CRC) remains a significant global health challenge despite survival improvements.
  • Advances include new treatment regimens, maintenance strategies, and multidisciplinary approaches for oligometastatic disease.

Purpose of the Study:

  • To review novel therapeutics and regimens for metastatic colorectal cancer (mCRC).
  • To discuss innovative combination and maintenance strategies using existing agents.
  • To highlight the integration of pharmacogenomics and non-invasive monitoring for personalized mCRC management.

Main Methods:

  • Literature review of recently approved and investigational therapies for mCRC.
  • Analysis of studies on combination and maintenance treatment strategies.
  • Examination of evidence supporting pharmacogenomic and non-invasive monitoring in mCRC.

Main Results:

  • Novel therapeutics and regimens are expanding treatment options for mCRC.
  • Repurposing older agents in novel combinations and maintenance strategies shows promise.
  • Pharmacogenomic data and non-invasive monitoring are crucial for personalized mCRC care.

Conclusions:

  • Personalized management of mCRC is evolving with new therapeutic approaches.
  • Integrating molecular insights and advanced monitoring can optimize treatment efficacy and reduce toxicity.
  • Continued research into novel agents and personalized strategies is essential for improving mCRC patient survival.
Keywords:
AngiogenesisEGFRRAFRASbiomarkerfluoropyrimidinesimmunotherapymetastatic colorectal cancermicrosatellite instabilitypharmacogenetics

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
137